When the clock speeds up early
For some women, the signs come early. Periods get irregular. Sleep goes rough. Mood dips. A doctor explains that the ovaries are slowing down sooner than expected.
Medicine calls this diminished ovarian reserve, or DOR. It means fewer eggs, lower hormones, and in many cases, harder pregnancies.
Current options are limited. Most doctors focus on fertility treatments, not on slowing the decline itself. A new trial asks a different question: can a simple supplement help?
A compound your body already craves
The supplement tested is called L-ergothioneine, or EGT for short. It is an antioxidant made by certain fungi. You get it naturally from mushrooms, especially specialty ones like oyster and shiitake.
Your body cannot make EGT on its own. But it has a special transporter that pulls EGT into cells and keeps it there. That hints EGT does something important. Scientists have long suspected it protects mitochondria, the tiny power plants inside cells.
Eggs in the ovary depend heavily on mitochondria. Damage there is one leading theory for why fertility fades with age.
The old way vs. a new angle
Doctors usually treat diminished ovarian reserve with hormones or assisted reproduction. Those tools work but do not address the root cause.
EGT is different. It targets oxidative stress, the cellular wear-and-tear that damages mitochondria over time. The idea is to slow the damage, not just paper over its effects.
Before this study, researchers had lab evidence that EGT protected egg cells in a dish and in animal studies. What was missing was human data.
How it works, in simple terms
Picture your cells like tiny cities. Mitochondria are the power plants keeping the lights on. Oxidative stress is rust. Over the years, rust builds up and the grid starts failing.
EGT works like a shield. It absorbs some of the damaging particles before they can corrode anything. Apply it where it is needed most, and the cells should run cleaner.
The study snapshot
Researchers in China enrolled 40 women aged 35 to 45 with diagnosed diminished ovarian reserve and menstrual problems. Each woman took 120 mg of EGT orally every day for three menstrual cycles.
This was not a placebo-controlled trial. Every woman knew she was getting the supplement. The team tracked hormones, ultrasound findings, and symptom questionnaires before and after.
Here's what they found
Thirty-six women finished the trial. No one reported side effects from the supplement.
Key hormones moved in the right direction. AMH, a measure of how many eggs the ovaries still hold, rose from about 1.8 to 2.5 ng/mL on average. FSH, which tends to go up as ovaries weaken, dropped. Estrogen levels rose.
Symptoms improved alongside the numbers. Hot flashes and night sweats eased. Sleep scores improved. Menstrual symptom scores improved. Quality of life scores went up.
The changes in hormones even lined up with the changes in symptoms. Better hormone balance tracked with better sleep.
This is where things get interesting.
The gains showed up in both the younger and older subgroups in the study. That suggests EGT may help across the late-reproductive years, not just in one narrow window.
How the researchers read it
The study authors describe their work as a "proof-of-concept." They are careful. They note that every improvement could also come partly from the natural ups and downs of menstrual cycles, or from the attention of being in a study.
They call for larger, placebo-controlled trials next. Until then, this is a hopeful signal, not a proven therapy.
If you have been told your ovarian reserve is low, do not start EGT on your own based on this single study. Forty women is a small group. Without a placebo arm, we cannot fully trust the size of the effect.
But it is worth knowing that research in this space is moving. Talk to a reproductive specialist if you are worried. Ask about current evidence and your personal options, including fertility preservation if that matters for your plans.
Also, mushrooms are a fine food to enjoy. Just do not expect the amount in a stir-fry to match a research dose.
The limits
Besides being small and open-label, the trial was run at one center. The researchers enrolled only women with moderately low AMH, so we do not know if EGT helps women with severely reduced reserve.
And we still do not have long-term follow-up. Did the improvements hold after stopping EGT? The study did not look.
A placebo-controlled trial is the logical next step. Researchers will also want to test whether EGT helps fertility outcomes like pregnancy rates, not just hormone readouts.
If it passes those harder tests, EGT could join a growing list of mitochondria-focused therapies aimed at helping people age better. For now, it is one piece of early but intriguing evidence.
